male
past
medic
histori
hypertens
diabet
mellitu
acut
myelogen
leukemia
aml
underw
allogen
hematopoiet
stem
cell
transplant
hsct
present
recurr
fever
cough
patient
undergon
allogen
hsct
match
unrel
donor
month
previous
condit
fludarabin
melphalan
alemtuzumab
posttranspl
cours
complic
graft
versu
host
diseas
multipl
central
venou
cathet
infect
coagulaseneg
staphylococcu
spp
vancomycinresist
enterococcu
lactobacillu
alphahemolyt
streptococcu
initi
cours
also
develop
nodular
pneumonia
subsequ
workup
includ
bronchoscopi
nondiagnost
pneumonia
resolv
empir
posaconazol
treatment
sixteen
month
transplant
patient
develop
fatigu
lowgrad
fever
cough
chest
xray
cxr
show
new
left
lower
lobe
infiltr
sputum
cultur
grew
fluoroquinolonesuscept
pseudomona
oncolog
servic
subsequ
discharg
patient
home
moxifloxacin
alon
three
week
later
present
recurr
cough
fever
readmit
cxr
show
new
right
lower
lobe
infiltr
patient
remot
histori
symptomat
bradycardia
undergon
pacemak
placement
former
cigarett
smoker
packyear
deni
intraven
drug
use
retir
automobil
mechan
live
home
wife
dog
travel
recent
la
vega
short
trip
visit
casino
medic
admiss
includ
acyclovir
fluconazol
dapson
prophylaxi
previous
advers
reaction
imipenem
caus
rash
voriconazol
caus
visual
hallucin
physic
examin
alert
orient
temperatur
heart
rate
beat
per
minut
blood
pressur
mmhg
respiratori
rate
breath
per
minut
oxygen
satur
ambient
air
mild
bilater
crackl
lung
base
wellheal
nontend
nonerythemat
surgic
scar
site
pacemak
pocket
anterior
chest
wall
remaind
physic
examin
unremark
laboratori
valu
signific
pancytopenia
wbc
count
neutrophil
lymphocyt
monocyt
hemoglobin
gdl
normal
rang
g
dl
platelet
count
normal
rang
laboratori
male
past
medic
histori
hypertens
diabet
mellitu
acut
myelogen
leukemia
aml
underw
allogen
hematopoiet
stem
cell
transplant
hsct
present
recurr
fever
cough
patient
undergon
allogen
hsct
match
unrel
donor
month
previous
condit
fludarabin
melphalan
alemtuzumab
posttranspl
cours
complic
graft
versu
host
diseas
multipl
central
venou
cathet
infect
coagulaseneg
staphylococcu
spp
vancomycinresist
enterococcu
lactobacillu
alphahemolyt
streptococcu
initi
cours
also
develop
nodular
pneumonia
subsequ
workup
includ
bronchoscopi
nondiagnost
pneumonia
resolv
empir
posaconazol
treatment
sixteen
month
transplant
patient
develop
fatigu
lowgrad
fever
cough
chest
xray
cxr
show
new
left
lower
lobe
infiltr
sputum
cultur
grew
fluoroquinolonesuscept
pseudomona
oncolog
servic
subsequ
discharg
patient
home
moxifloxacin
alon
three
week
later
present
recurr
cough
fever
readmit
cxr
show
new
right
lower
lobe
infiltr
patient
remot
histori
symptomat
bradycardia
undergon
pacemak
placement
former
cigarett
smoker
packyear
deni
intraven
drug
use
retir
automobil
mechan
live
home
wife
dog
travel
recent
la
vega
short
trip
visit
casino
medic
admiss
includ
acyclovir
fluconazol
dapson
prophylaxi
previous
advers
reaction
imipenem
caus
rash
voriconazol
caus
visual
hallucin
physic
examin
alert
orient
temperatur
heart
rate
beat
per
minut
blood
pressur
mmhg
respiratori
rate
breath
per
minut
oxygen
satur
ambient
air
mild
bilater
crackl
lung
base
wellheal
nontend
nonerythemat
surgic
scar
site
pacemak
pocket
anterior
chest
wall
remaind
physic
examin
unremark
laboratori
valu
signific
pancytopenia
wbc
count
neutrophil
lymphocyt
monocyt
hemoglobin
gdl
normal
rang
g
dl
platelet
count
normal
rang
laboratori
studi
includ
basic
metabol
panel
liver
function
test
lactat
dehydrogenas
ldh
total
protein
albumin
normal
two
set
blood
cultur
peripher
blood
epsteinbarr
viru
ebv
cytomegaloviru
cmv
polymeras
chain
reaction
pcr
serum
aspergillu
antigen
legionella
urinari
antigen
test
uat
pneumococcaluat
histoplasmauat
neg
nasal
swab
test
posit
parainfluenza
direct
fluoresc
antibodi
dfa
sputum
cultur
grew
normal
flora
highresolut
comput
tomographi
ct
scan
lung
show
bilater
interstiti
nodular
infiltr
fig
patient
fever
present
sign
congest
heart
failur
expos
radiat
receiv
drug
known
caus
lung
injuri
receiv
blood
transfus
suspect
symptom
like
due
infect
parainfluenza
viru
piv
dfa
test
came
back
posit
therefor
decid
treat
empir
antibiot
cover
common
bacteri
pathogen
caus
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
differenti
diagnosi
diffus
interstiti
infiltr
immunocompromis
patient
present
tabl
patient
treat
intraven
iv
vancomycin
iv
aztreonam
inhal
ribavirin
day
howev
becam
progress
hypox
next
day
serial
cxr
demonstr
develop
interstiti
pattern
diffus
infiltr
aminoglycosid
ad
cover
possibl
antibioticresist
pseudomona
pneumonia
show
signific
improv
subsequ
bronchoscopi
without
transbronchi
biopsi
rule
etiolog
bronchoalveolar
lavag
bal
specimen
sent
gram
stain
bacteri
cultur
acidfast
bacillu
afb
smear
cultur
fungal
viral
cultur
pneumocysti
jirovecii
dfa
test
neg
nevertheless
began
empir
therapi
p
jirovecii
pneumonia
pjp
clindamycin
primaquin
also
restart
inhal
ribavirin
next
sever
day
patient
dyspnea
progress
ultim
necessit
intub
extens
discuss
underw
videoassist
thoracoscopi
lung
biopsi
histopatholog
find
consist
viral
infect
dfa
test
posit
p
jirovecii
patient
deterior
clindamycin
primaquin
therapi
chang
trimethoprimsulfamethoxazol
tmpsmx
subsequ
success
extub
wean
room
air
transfer
rehabilit
facil
followup
visit
well
confirm
efficaci
pjp
therapi
resolut
piv
pneumonia
one
month
later
unfortun
readmit
hospit
sepsi
extens
workup
fail
reveal
etiolog
develop
multisystem
organ
failur
expir
autopsi
perform
parainfluenza
virus
piv
envelop
rna
virus
famili
paramyxovirida
piv
common
respiratori
pathogen
known
primarili
caus
infect
children
howev
immun
incomplet
reinfect
occur
piv
infect
immunocompromis
patient
particularli
set
hematolog
malign
solid
organ
transplant
hsct
increasingli
recogn
associ
wide
spectrum
diseas
rang
mild
upper
respiratori
symptom
pneumon
sever
respiratori
failur
mortal
rate
piv
lower
respiratori
diseas
vari
among
studi
reach
report
piv
infect
suspect
diagnosi
made
primarili
detect
piv
antigen
direct
indirect
fluoresc
antibodi
test
nasopharyng
wash
swab
bal
test
limit
sensit
high
specif
viral
cultur
also
use
may
take
sever
day
return
posit
piv
pcr
highli
sensit
specif
may
readili
avail
may
take
time
antibodi
assay
recent
multiplex
pcr
test
becom
avail
multipl
respiratori
pathogen
includ
parainfluenza
virus
univers
chicago
lab
current
perform
pcr
amplif
method
analysi
autom
nest
multiplex
pcr
commerci
avail
assay
test
perform
hous
everyday
turnov
detect
import
respiratori
virus
influenza
influenza
subtyp
influenza
b
respiratori
syncyti
viru
parainfluenza
virus
type
adenoviru
human
metapneumoviru
coronaviru
enterovirusrhinoviru
three
bacteri
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
ct
scan
lung
usual
prefer
imag
modal
identifi
pulmonari
abnorm
radiograph
find
piv
infect
variabl
focal
diffus
interstiti
alveolarinterstiti
infiltr
studi
suggest
multipl
small
noncavit
pulmonari
nodul
might
indic
viral
etiolog
pneumonia
piv
current
antivir
approv
treatment
piv
small
studi
case
report
shown
mix
result
regard
clinic
benefit
aerosol
system
ribavirin
without
iv
gamma
globulin
major
studi
date
fail
demonstr
improv
outcom
treat
patient
term
progress
pneumonia
need
mechan
ventil
durat
ill
mortal
mani
patient
studi
respiratori
copathogen
associ
higher
mortal
organ
identifi
includ
mix
viral
infect
eg
cmv
adenoviru
respiratori
syncyti
viru
superimpos
bacteri
fungal
infect
particularli
aspergillosi
mycobacteri
infect
dual
infect
p
jirovecii
respiratori
viru
also
report
recent
sialidas
fusion
protein
cleav
alpha
gal
linkag
sialic
acid
respiratori
endotheli
cell
surfac
use
hsct
recipi
piv
infect
pneumonia
complet
clinic
respons
patient
partial
control
group
studi
drug
administ
either
oral
inhal
use
dri
powder
inhal
nebul
intub
patient
target
host
protein
piv
bind
rather
viral
structur
pjp
caus
fungu
p
jirovecii
previous
known
p
carinii
howev
p
carinii
understood
separ
speci
infect
rodent
wherea
p
jirovecii
infect
human
henc
name
chang
p
jirovecii
infect
diagnos
person
infect
human
immunodefici
viru
hiv
absolut
lymphocyt
count
cellsmm
nonhivinfect
immunocompromis
patient
increas
risk
invas
fungal
infect
includ
p
jirovecii
consequ
prophylaxi
recommend
tmpsmx
howev
tmpsmx
use
limit
advers
reaction
skin
rash
nausea
vomit
nephrotox
bone
marrow
suppress
dapson
consid
accept
altern
despit
higher
rate
breakthrough
infect
nonhivinfect
patient
pjp
demonstr
acut
clinic
cours
often
delay
treatment
initi
higher
mortal
compar
patient
hiv
infect
tmpsmx
remain
treatment
choic
base
primarili
studi
hivinfect
patient
p
jirovecii
cultur
diagnosi
requir
identif
organ
stain
fluid
induc
sputum
bal
lung
biopsi
specimen
microscopi
dfa
stain
becom
commonli
use
method
studi
among
immunocompromis
patient
without
hiv
lower
organ
burden
poorer
diagnost
yield
convent
stain
specimen
induc
sputum
bal
although
p
jirovecii
realtim
pcr
higher
sensit
specif
dfa
particularli
use
popul
test
may
abl
differenti
colon
true
infect
therefor
tissu
sampl
diagnosi
may
necessari
confirm
pjp
nonhivinfect
patient
key
pointspearl
differenti
diagnosi
pulmonari
infiltr
immunocompromis
host
broad
detail
histori
workup
essenti
establish
specif
etiolog
tissu
sampl
frequent
need
establish
definit
diagnosi
pjp
nonhivinfect
immunocompromis
patient
multipl
simultan
infecti
noninfecti
patholog
process
common
immunocompromis
patient
pjp
consid
differenti
diagnosi
patient
hiv
well
immunocompromis
patient
without
hiv
present
pneumonia
mainstay
therapi
piv
infect
remain
support
given
lack
evid
support
use
ribavirin
iv
gamma
globulin
although
sialidas
fusion
protein
cleav
alpha
gal
linkag
sialic
acid
respiratori
endotheli
cell
surfac
use
altern
clindamycin
plu
primaquin
test
defici
pentamidin
much
toxic
prognosi
pjp
nonhivinfect
immunocompromis
patient
wors
like
due
delay
diagnosi
acut
present
